Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Inflammatory Bowel Diseases

Free Subscription Articles published in Scand J Gastroenterol Retrieve available abstracts of 156 articles: HTML format

Single Articles

November 2023
1. HARNO-TASIHIN J, Siregar L, Paajanen M, Arkkila P, et al
   Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses.
   Scand J Gastroenterol. 2023 Nov 25:1-8. doi: 10.1080/00365521.2023.2285229.
   PubMed     Abstract available
   
   
   
2. ZHANG Y, Jiang W, Xu C, Tian J, et al
   The impact of proactive versus reactive drug monitoring of infliximab on treatment outcomes in patients with crohn's disease.
   Scand J Gastroenterol. 2023 Nov 22:1-11. doi: 10.1080/00365521.2023.2283387.
   PubMed     Abstract available
   
   
   
3. ANJIE SI, Hanzel J, Gecse KB, D'Haens GR, et al
   Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies.
   Scand J Gastroenterol. 2023 Nov 14:1-7. doi: 10.1080/00365521.2023.2278424.
   PubMed     Abstract available
   
   
   
4. IBORRA M, Ferreiro-Iglesias R, Maria Dolores MA, Mesonero Gismero F, et al
   Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort.
   Scand J Gastroenterol. 2023 Nov 6:1-9. doi: 10.1080/00365521.2023.2278427.
   PubMed     Abstract available
   
   
   October 2023
5. WANG L, Zhang Y, Wu H, Tang Z, et al
   Intestinal ultrasound score predicts therapeutic outcomes of infliximab in pediatric patients with Crohn's disease.
   Scand J Gastroenterol. 2023 Oct 31:1-8. doi: 10.1080/00365521.2023.2271110.
   PubMed     Abstract available
   
   
   
6. NURMI E, Rantanen A, Paavilainen E, Haapamaki J, et al
   A quality assessment of inflammatory bowel disease nursing care in Finland: a nationwide cross-sectional descriptive study.
   Scand J Gastroenterol. 2023 Oct 30:1-5. doi: 10.1080/00365521.2023.2276654.
   PubMed     Abstract available
   
   
   
7. YAN Q, Feng Z, Jiang B, Yao J, et al
   Biological functions of connexins in the development of inflammatory bowel disease.
   Scand J Gastroenterol. 2023 Oct 14:1-8. doi: 10.1080/00365521.2023.2267713.
   PubMed     Abstract available
   
   
   September 2023
8. FOSSMARK R, Lirhus SS, Hoivik ML
   The impact of proton pump inhibitors on the course of ulcerative colitis: a cohort study of over 10,000 newly diagnosed patients in Norway.
   Scand J Gastroenterol. 2023 Sep 8:1-6. doi: 10.1080/00365521.2023.2255710.
   PubMed     Abstract available
   
   
   August 2023
9. RANKALA R, Mustonen A, Voutilainen M, Mattila K, et al
   Costs of medications used to treat inflammatory bowel disease.
   Scand J Gastroenterol. 2023 Aug 29:1-5. doi: 10.1080/00365521.2023.2248539.
   PubMed     Abstract available
   
   
   
10. ZHANG X, Wang P, Yang Y, Gao X, et al
    Monocyte/macrophage mediates the impact of depression on Crohn's disease.
    Scand J Gastroenterol. 2023 Aug 27:1-11. doi: 10.1080/00365521.2023.2245938.
    PubMed     Abstract available
    
    
    
11. CHEN Y, Sun Z, Li Z, Duan M, et al
    Comparison of endoscopic balloon dilation and surgery for duodenal stricture in patients with Crohn's disease.
    Scand J Gastroenterol. 2023 Aug 25:1-7. doi: 10.1080/00365521.2023.2250495.
    PubMed     Abstract available
    
    
    
12. CHEN C, Lan B, Xie G, Liu Z, et al
    Analysis and identification of ferroptosis-related genes in ulcerative colitis.
    Scand J Gastroenterol. 2023 Aug 2:1-12. doi: 10.1080/00365521.2023.2240927.
    PubMed     Abstract available
    
    
    July 2023
13. KIM J, Jung JH, Jo H, Kim MH, et al
    Risk of uterine cervical cancer in inflammatory bowel disease: a systematic review and meta-analysis.
    Scand J Gastroenterol. 2023 Jul 30:1-10. doi: 10.1080/00365521.2023.2238101.
    PubMed     Abstract available
    
    
    
14. BRODERSEN JB, Jensen MD, Juel MA, Kjeldsen J, et al
    Intestinal ultrasound in patients with suspected Crohn's disease - results of a prospective evaluation by trainees.
    Scand J Gastroenterol. 2023 Jul 17:1-7. doi: 10.1080/00365521.2023.2234538.
    PubMed     Abstract available
    
    
    
15. BARNER-RASMUSSEN N, Sjoblom N, Arola J, Boyd S, et al
    The role of serology, liver function tests and imaging in screening of primary sclerosing cholangitis: the HelPSCreen score.
    Scand J Gastroenterol. 2023 Jul 14:1-8. doi: 10.1080/00365521.2023.2233038.
    PubMed     Abstract available
    
    
    
16. MARK-CHRISTENSEN A, Jolving LR, Anru PL, Murray JA, et al
    A population-based nationwide study on total colectomy for ulcerative colitis and risk of ten prevalent inflammatory or autoimmune diseases.
    Scand J Gastroenterol. 2023 Jul 6:1-7. doi: 10.1080/00365521.2023.2231586.
    PubMed     Abstract available
    
    
    
17. KATO I, Minkevitch J, Sun J
    Oncogenic potential of Campylobacter infection in the gastrointestinal tract: narrative review.
    Scand J Gastroenterol. 2023;58:1453-1465.
    PubMed     Abstract available
    
    
    June 2023
18. BANZRAGCH M, Sanli K, Stensvold CR, Kurt O, et al
    Metabarcoding of colonic cleansing fluid reveals unique bacterial members of mucosal microbiota associated with Inflammatory Bowel Disease.
    Scand J Gastroenterol. 2023 Jun 20:1-11. doi: 10.1080/00365521.2023.2223708.
    PubMed     Abstract available
    
    
    
19. FOLLIN-ARBELET B, Smastuen MC, Hovde O, Jelsness-Jorgensen LP, et al
    Incidence of cancer in patients with ulcerative colitis 30 years after diagnosis (the IBSEN study).
    Scand J Gastroenterol. 2023 Jun 20:1-7. doi: 10.1080/00365521.2023.2223709.
    PubMed     Abstract available
    
    
    
20. KIASAT A, Rautiainen S, Prast-Nielsen S, Engstrand L, et al
    Evaluation of plasma Short chain fatty acid levels as markers for Inflammatory bowel disease.
    Scand J Gastroenterol. 2023 Jun 5:1-7. doi: 10.1080/00365521.2023.2219357.
    PubMed     Abstract available
    
    
    May 2023
21. BEYSENS S, Wellens J, De Hertogh G, Van Laethem A, et al
    Managing metastatic Crohn's disease: a single center experience, review of the current evidence, and treatment algorithm.
    Scand J Gastroenterol. 2023 May 13:1-9. doi: 10.1080/00365521.2023.2209689.
    PubMed     Abstract available
    
    
    
22. KIM KW, Koh SJ, Kang HW, Park H, et al
    Atopic dermatitis is associated with the clinical course of inflammatory bowel disease.
    Scand J Gastroenterol. 2023 May 11:1-7. doi: 10.1080/00365521.2023.2209688.
    PubMed     Abstract available
    
    
    
23. SHI T, Liu W, Li T, Liu H, et al
    HLA-DQ genotype distribution and risk evaluation of celiac disease in Northwest China.
    Scand J Gastroenterol. 2023;58:471-476.
    PubMed     Abstract available
    
    
    April 2023
24. LIU C, Zhan S, Li N, Tu T, et al
    Bile acid alterations associated with indolent course of inflammatory bowel disease.
    Scand J Gastroenterol. 2023 Apr 18:1-10. doi: 10.1080/00365521.2023.2200518.
    PubMed     Abstract available
    
    
    
25. ZHU M, Fan L, Han M, Zhu S, et al
    The usefulness of fecal hemoglobin and calprotectin tests in diagnosing significant bowel diseases: a prospective study.
    Scand J Gastroenterol. 2023;58:368-374.
    PubMed     Abstract available
    
    
    
26. KRIDIN K, Goral D, Shihade W, Tzur-Bitan D, et al
    Vitiligo and Crohn's disease form an autoimmune cluster: insights from a population-based study.
    Scand J Gastroenterol. 2023;58:354-359.
    PubMed     Abstract available
    
    
    March 2023
27. PAUWELS RWM, Ten Bokkel Huinink S, van der Woude CJ, Doukas M, et al
    Early fecal calprotectin levels at week 8 may guide therapeutic decisions on Ustekinumab therapy in patients with Crohn's disease.
    Scand J Gastroenterol. 2023 Mar 27:1-8. doi: 10.1080/00365521.2023.2194009.
    PubMed     Abstract available
    
    
    
28. LIU Y, Ji X, Huang Y, Li Q, et al
    Older patients benefit more from sequential courses of washed microbiota transplantation than younger population with ulcerative colitis.
    Scand J Gastroenterol. 2023 Mar 2:1-10. doi: 10.1080/00365521.2023.2185476.
    PubMed     Abstract available
    
    
    February 2023
29. PAN Y, Huang X, Zhou Z, Yang X, et al
    Clinical significance of a novel uric-acid-based biomarker in the prediction of disease activity and response to infliximab therapy in Crohn's disease.
    Scand J Gastroenterol. 2023 Feb 24:1-7. doi: 10.1080/00365521.2023.2175181.
    PubMed     Abstract available
    
    
    
30. WANG L, Xu C, Zhang Y, Jiang W, et al
    External validation and comparison of simple ultrasound activity score and international bowel ultrasound segmental activity score for Crohn's disease.
    Scand J Gastroenterol. 2023 Feb 23:1-7. doi: 10.1080/00365521.2023.2181038.
    PubMed     Abstract available
    
    
    
31. JENSEN KJ, Jensen CB, Wennerstrom C, Burisch J, et al
    Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
    Scand J Gastroenterol. 2023 Feb 21:1-11. doi: 10.1080/00365521.2023.2173988.
    PubMed     Abstract available
    
    
    
32. WIKEN TH, Hoivik ML, Buer L, Warren DJ, et al
    Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring.
    Scand J Gastroenterol. 2023 Feb 17:1-11. doi: 10.1080/00365521.2023.2176252.
    PubMed     Abstract available
    
    
    
33. JORGENSEN KK, Hoivik ML, Chopra A, Benth JS, et al
    Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type.
    Scand J Gastroenterol. 2023 Feb 14:1-9. doi: 10.1080/00365521.2023.2177884.
    PubMed     Abstract available
    
    
    
34. LINDH S, Bengtsson J, Kaczynski J
    Is biologic therapy effective for antibiotic-refractory pouchitis?
    Scand J Gastroenterol. 2023;58:148-150.
    PubMed     Abstract available
    
    
    December 2022
35. ARMS-WILLIAMS B, Hawthorne AB, Cannings-John R, Berry A, et al
    Changes in incidence and clinical features of inflammatory bowel disease in Cardiff, UK over 50 years: an update for 2005-2016.
    Scand J Gastroenterol. 2022 Dec 23:1-8. doi: 10.1080/00365521.2022.2158754.
    PubMed     Abstract available
    
    
    
36. DANDOY P, Louis E, Gast P, Poncin M, et al
    Factors associated with the efficacy and safety of endoscopic dilatation of symptomatic strictures in Crohn's disease: a retrospective cohort study.
    Scand J Gastroenterol. 2022 Dec 19:1-9. doi: 10.1080/00365521.2022.2156808.
    PubMed     Abstract available
    
    
    
37. RUEDA GARCIA JL, Suarez Ferrer C, Martin-Arranz E, Garcia-Ramirez L, et al
    Randomized clinical trial evaluating three low-volume preparations for colonoscopy in outpatients with Inflammatory Bowel Disease: the EII-PREP trial.
    Scand J Gastroenterol. 2022 Dec 15:1-8. doi: 10.1080/00365521.2022.2153618.
    PubMed     Abstract available
    
    
    
38. CARON B, Laurent V, Odille F, Danese S, et al
    New magnetic resonance imaging sequences for fibrosis assessment in Crohn's disease: a pilot study.
    Scand J Gastroenterol. 2022;57:1450-1453.
    PubMed     Abstract available
    
    
    
39. GAWEL K, Dabkowski K, Zawada I, Starzynska T, et al
    Progression risk factors of ulcerative proctitis.
    Scand J Gastroenterol. 2022;57:1406-1411.
    PubMed     Abstract available
    
    
    November 2022
40. ERONEN H, Oksanen P, Jussila A, Huhtala H, et al
    Long-term outcomes of patients with acute severe ulcerative colitis treated with cyclosporine rescue therapy.
    Scand J Gastroenterol. 2022 Nov 17:1-6. doi: 10.1080/00365521.2022.2143727.
    PubMed     Abstract available
    
    
    
41. KRARUP AL, Larsen L, Nayeb AB, Grontved S, et al
    Less prevalent use of biologics for inflammatory bowel disease in patients from Non-Academic hospitals - a Danish register-based study of a region with 580,000 citizens.
    Scand J Gastroenterol. 2022 Nov 10:1-6. doi: 10.1080/00365521.2022.2143726.
    PubMed     Abstract available
    
    
    
42. GOETGEBUER RL, van der Woude CJ, Bakker L, van der Eijk AA, et al
    The diagnosis and management of CMV colitis in IBD patients shows high practice variation: a national survey among gastroenterologists.
    Scand J Gastroenterol. 2022;57:1321-1326.
    PubMed     Abstract available
    
    
    
43. YU L, Zhang MM, Hou JG
    Molecular and cellular pathways in colorectal cancer: apoptosis, autophagy and inflammation as key players.
    Scand J Gastroenterol. 2022;57:1279-1290.
    PubMed     Abstract available
    
    
    
44. BLESL A, Petritsch W, Binder L, Furst S, et al
    Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
    Scand J Gastroenterol. 2022;57:1327-1330.
    PubMed     Abstract available
    
    
    
45. BRUNET-HOUDARD S, Monmousseau F, Berthon G, Des Garets V, et al
    How are patients' preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn's disease patients.
    Scand J Gastroenterol. 2022;57:1312-1320.
    PubMed     Abstract available
    
    
    
46. LEE CH, Huang S, Hsu P, Leong RW, et al
    Low-dose IL-2 may enhance the effect of vedolizumab.
    Scand J Gastroenterol. 2022;57:1404-1405.
    PubMed    
    
    
    October 2022
47. SHIGA H, Takahashi T, Shiraki M, Kojima Y, et al
    Reduced antiviral seropositivity among patients with inflammatory bowel disease treated with immunosuppressive agents.
    Scand J Gastroenterol. 2022 Oct 12:1-8. doi: 10.1080/00365521.2022.2132831.
    PubMed     Abstract available
    
    
    
48. NISHIO M, Hirasawa K, Chiba S, Ozeki Y, et al
    Endoscopic resection is feasible for high-grade dysplasia in patients with ulcerative colitis.
    Scand J Gastroenterol. 2022 Oct 6:1-6. doi: 10.1080/00365521.2022.2107878.
    PubMed     Abstract available
    
    
    September 2022
49. MANGIA M, Giuffrida E, Figini V, Colombo A, et al
    Agreement between patients and physicians on scores of inflammatory bowel disease activity and burden assessed on a telemonitoring platform.
    Scand J Gastroenterol. 2022 Sep 23:1-8. doi: 10.1080/00365521.2022.2124538.
    PubMed     Abstract available
    
    
    
50. GROS B, Soto P, Causse M, Marin S, et al
    Impact of Clostridioides difficile infection in patients admitted with ulcerative colitis.
    Scand J Gastroenterol. 2022 Sep 8:1-8. doi: 10.1080/00365521.2022.2121175.
    PubMed     Abstract available
    
    
    August 2022
51. BJORLYKKE KH, Jahnsen J, Brynskov J, Molander P, et al
    Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia.
    Scand J Gastroenterol. 2022 Aug 23:1-9. doi: 10.1080/00365521.2022.2108684.
    PubMed     Abstract available
    
    
    
52. BOAZ E, Bar-Gil Shitrit A, Schechter M, Goldin E, et al
    Inflammatory bowel disease in families with four or more affected first-degree relatives.
    Scand J Gastroenterol. 2022 Aug 5:1-5. doi: 10.1080/00365521.2022.2106153.
    PubMed     Abstract available
    
    
    
53. SAJJADI S, Svensson Neufert R, Ruhr E, Tryggmo S, et al
    Emergency subtotal colectomy rates in relation to anti-TNF therapy in inflammatory bowel disease patients: comparison of retrospective cohorts.
    Scand J Gastroenterol. 2022 Aug 2:1-5. doi: 10.1080/00365521.2022.2106151.
    PubMed     Abstract available
    
    
    
54. LERANG F, Holst R, Henriksen M, Wahlberg H, et al
    Antitumour necrosis factor alpha treatment in Crohn's disease: long-term efficacy, side effects and need for surgery.
    Scand J Gastroenterol. 2022;57:921-929.
    PubMed     Abstract available
    
    
    July 2022
55. WONG ECL, Hasan B, Dulai PS, Marshall JK, et al
    End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis.
    Scand J Gastroenterol. 2022 Jul 30:1-8. doi: 10.1080/00365521.2022.2105169.
    PubMed     Abstract available
    
    
    
56. HELLSTROM PM, Gemmen E, Ward HA, Koo H, et al
    Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study.
    Scand J Gastroenterol. 2022 Jul 14:1-8. doi: 10.1080/00365521.2022.2090275.
    PubMed     Abstract available
    
    
    
57. MEYER A, Fumery M, Peyrin-Biroulet L, Filippi J, et al
    Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study.
    Scand J Gastroenterol. 2022 Jul 12:1-9. doi: 10.1080/00365521.2022.2095668.
    PubMed     Abstract available
    
    
    
58. BOKS M, Lilja M, Widerstrom M, Karling P, et al
    Increased incidence of late-onset inflammatory bowel disease and microscopic colitis after a Cryptosporidium hominis outbreak.
    Scand J Gastroenterol. 2022 Jul 8:1-7. doi: 10.1080/00365521.2022.2094722.
    PubMed     Abstract available
    
    
    
59. LUKAS M, Kolar M, Reissigova J, Duricova D, et al
    A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts.
    Scand J Gastroenterol. 2022;57:814-824.
    PubMed     Abstract available
    
    
    June 2022
60. KOUKI M, Caron B, Malgras A, Ayav A, et al
    Weight change after colectomy for ulcerative colitis.
    Scand J Gastroenterol. 2022 Jun 20:1-3. doi: 10.1080/00365521.2022.2089537.
    PubMed     Abstract available
    
    
    
61. BAUER N, Kairey L, Schlee C, Uecker C, et al
    Use of complementary and alternative medicine (CAM) in patients with inflammatory bowel disease (IBD): results from a German nationwide survey of 2019 compared to a previous survey of 2002.
    Scand J Gastroenterol. 2022 Jun 18:1-7. doi: 10.1080/00365521.2022.2078667.
    PubMed     Abstract available
    
    
    
62. PUOLANNE AM, Qadri S, Vesterinen T, Hiltunen S, et al
    Can dysplasia surveillance be better targeted in ulcerative colitis by using faecal calprotectin?
    Scand J Gastroenterol. 2022 Jun 13:1-8. doi: 10.1080/00365521.2022.2084345.
    PubMed     Abstract available
    
    
    May 2022
63. FERNANDES SR, Rodrigues IC, Serrazina J, Botto IA, et al
    Proactive infliximab is more effective than vedolizumab in inducing fecal calprotectin remission in inflammatory bowel disease.
    Scand J Gastroenterol. 2022 May 22:1-7. doi: 10.1080/00365521.2022.2076567.
    PubMed     Abstract available
    
    
    
64. MONMOUSSEAU F, Mulot L, Rusch E, Picon L, et al
    Predictors of each quality of life dimension in Crohn's disease patients initiating an anti-TNF treatment: differentiated effects of patient-, disease-, and treatment-related characteristics.
    Scand J Gastroenterol. 2022;57:566-573.
    PubMed     Abstract available
    
    
    April 2022
65. CHRISTENSEN KR, Ainsworth MA, Steenholdt C, Buhl S, et al
    Fatigue is a systemic extraintestinal disease manifestation largely independent of disease activity, chronicity, and nutritional deficiencies in inflammatory bowel disease on biologics.
    Scand J Gastroenterol. 2022 Apr 12:1-7. doi: 10.1080/00365521.2022.2060049.
    PubMed     Abstract available
    
    
    
66. VOLKERS A, Bossuyt P, de Jong J, Pouillon L, et al
    Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) study.
    Scand J Gastroenterol. 2022;57:439-445.
    PubMed     Abstract available
    
    
    
67. KIM JE, Won H, Kim YH, Kim ER, et al
    Specificity of clinical decision support tools for vedolizumab and ustekinumab in biologically naive patients with Crohn's disease.
    Scand J Gastroenterol. 2022;57:446-448.
    PubMed     Abstract available
    
    
    
68. HIRSCH RD, Keung C, Con D, Vasudevan A, et al
    Direct health care costs of managing perianal Crohn's Disease in a population based cohort.
    Scand J Gastroenterol. 2022;57:432-438.
    PubMed     Abstract available
    
    
    
69. YLISAUKKO-OJA T, Puttonen M, Jokelainen J, Koivusalo M, et al
    Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice.
    Scand J Gastroenterol. 2022;57:415-423.
    PubMed     Abstract available
    
    
    
70. BRODERSEN JB, Andersen KW, Jensen MD
    Adherence to the bowel cleansing regimen for pan-enteric capsule endoscopy in patients with suspected Crohn's disease and factors affecting the image quality.
    Scand J Gastroenterol. 2022;57:501-506.
    PubMed     Abstract available
    
    
    
71. HERMANSON M, Bengtson J, Croix H, Lindholm E, et al
    Ileal pouch-anal anastomosis; 18 years of experience and outcomes across two generations of surgeons at a tertiary center in Sweden.
    Scand J Gastroenterol. 2022;57:401-405.
    PubMed     Abstract available
    
    
    March 2022
72. REPO M, Pessi J, Wirtanen E, Hiltunen P, et al
    Frequency and clinical significance of histologic upper gastrointestinal tract findings in children with inflammatory bowel disease.
    Scand J Gastroenterol. 2022 Mar 31:1-5. doi: 10.1080/00365521.2022.2057197.
    PubMed     Abstract available
    
    
    
73. GAO X, Huang D, Yang LS, He AQ, et al
    Identification of gut microbiome and transcriptome changes in ulcerative colitis and pouchitis.
    Scand J Gastroenterol. 2022 Mar 11:1-11. doi: 10.1080/00365521.2022.2047221.
    PubMed     Abstract available
    
    
    
74. ERONEN H, Kolehmainen S, Koffert J, Koskinen I, et al
    Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study.
    Scand J Gastroenterol. 2022 Mar 3:1-6. doi: 10.1080/00365521.2022.2045350.
    PubMed     Abstract available
    
    
    February 2022
75. MATTILA K, Rankala R, Voutilainen M, Mustonen A, et al
    Inflammatory bowel disease: perceived impact on leisure-time activities.
    Scand J Gastroenterol. 2022 Feb 23:1-6. doi: 10.1080/00365521.2022.2042593.
    PubMed     Abstract available
    
    
    
76. APPEL CW, Pedersen SC, Nielsen AS, Larsen BF, et al
    Telemedicine based on patient-reported outcomes in management of patients with inflammatory bowel disease in a real-life setting - a before and after cohort study.
    Scand J Gastroenterol. 2022 Feb 23:1-7. doi: 10.1080/00365521.2022.2041083.
    PubMed     Abstract available
    
    
    
77. KHERA AJ, Chase JW, Stillman BC, Salzberg M, et al
    Pelvic floor behavioral treatment for fecal incontinence and constipation in quiescent inflammatory bowel disease.
    Scand J Gastroenterol. 2022 Feb 21:1-7. doi: 10.1080/00365521.2022.2039280.
    PubMed     Abstract available
    
    
    
78. WICKRAMASEKERA N, Coates E, Barr A, Lee MJ, et al
    Patient preferences for treatment in steroid resistant ulcerative colitis - a discrete-choice experiment.
    Scand J Gastroenterol. 2022 Feb 10:1-10. doi: 10.1080/00365521.2022.2036808.
    PubMed     Abstract available
    
    
    
79. HILON J, Alstad T, Hasseus B, Kashani H, et al
    Phenotype of Crohn's disease according to the Montreal classification in relation to dental health status.
    Scand J Gastroenterol. 2022;57:183-189.
    PubMed     Abstract available
    
    
    
80. O'GRADY J, Carey BW, Kavanagh RG, O'Connell A, et al
    Making computed tomography safer for patients with Crohn's disease.
    Scand J Gastroenterol. 2022;57:175-182.
    PubMed     Abstract available
    
    
    
81. ZHULINA Y, Udumyan R, Tysk C, Halfvarson J, et al
    Mortality in patients with Crohn's disease in Orebro, Sweden 1963-2010.
    Scand J Gastroenterol. 2022;57:158-164.
    PubMed     Abstract available
    
    
    January 2022
82. JELSNESS-JORGENSEN LP, Moum B, Grimstad T, Jahnsen J, et al
    The multidimensional fatigue inventory (MFI-20): psychometrical testing in a Norwegian sample of inflammatory bowel disease (IBD) patients.
    Scand J Gastroenterol. 2022 Jan 25:1-7. doi: 10.1080/00365521.2022.2029939.
    PubMed     Abstract available
    
    
    
83. GE C, Lu Y, Shen H, Zhu L, et al
    Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis.
    Scand J Gastroenterol. 2022 Jan 7:1-12. doi: 10.1080/00365521.2021.2022193.
    PubMed     Abstract available
    
    
    December 2021
84. WARD D, Neumann A, Hendel JW, Riis LB, et al
    Danish Society for Gastroenterology and Hepatology's clinical recommendations for colonoscopic surveillance for colorectal dysplasia and cancer in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2021 Dec 30:1-8. doi: 10.1080/00365521.2021.2022191.
    PubMed     Abstract available
    
    
    
85. DIGNASS AU, Paridaens K, Al Awadhi S, Begun J, et al
    Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis.
    Scand J Gastroenterol. 2021 Dec 21:1-8. doi: 10.1080/00365521.2021.2015801.
    PubMed     Abstract available
    
    
    
86. WYNNE J, Kozuch P
    Medical marijuana for inflammatory bowel disease: the highs and lows.
    Scand J Gastroenterol. 2021 Dec 17:1-9. doi: 10.1080/00365521.2021.1998604.
    PubMed     Abstract available
    
    
    
87. EL-DALLAL M, Saroufim A, Systrom H, Ballou S, et al
    Assessing the repercussions of COVID-19 pandemic on symptoms, disease management, and emotional well-being in patients with inflammatory bowel disease: a multi-site survey study.
    Scand J Gastroenterol. 2021 Dec 11:1-9. doi: 10.1080/00365521.2021.2013527.
    PubMed     Abstract available
    
    
    
88. ZHANG M, Bai X, Zhang H, You Y, et al
    The role of cytomegalovirus colitis on short- and long-term outcomes for patients with ulcerative colitis.
    Scand J Gastroenterol. 2021 Dec 11:1-8. doi: 10.1080/00365521.2021.2006298.
    PubMed     Abstract available
    
    
    
89. WALTER S, Jones MP, Sjodahl J, Stjernman H, et al
    Measuring the impact of gastrointestinal inconvenience and symptoms on perceived health in the general population - validation of the Short Health Scale for gastrointestinal symptoms (SHS-GI).
    Scand J Gastroenterol. 2021;56:1406-1413.
    PubMed     Abstract available
    
    
    
90. LUNDQUIST LR, Rasmussen B, Waldorff FB, Wehberg S, et al
    Predictors of health-related quality of life in patients with Crohn's disease receiving biological therapy.
    Scand J Gastroenterol. 2021;56:1434-1441.
    PubMed     Abstract available
    
    
    
91. WEI Y, Chen T, Yang W, Li H, et al
    Detection of a novel antigen for Crohn's disease.
    Scand J Gastroenterol. 2021;56:1427-1433.
    PubMed     Abstract available
    
    
    
92. HAN ZM, Chen BX, Zhou Q, Liu HB, et al
    Predictors of infliximab-induced deep remission in treatment-naive patients with isolated small bowel Crohn's disease.
    Scand J Gastroenterol. 2021;56:1422-1426.
    PubMed     Abstract available
    
    
    November 2021
93. GRIMSTAD T, Skjellerudsveen BM, Kvaloy JT, Skoie IM, et al
    The influence of disease activity on fatigue in patients with ulcerative colitis - a longitudinal study.
    Scand J Gastroenterol. 2021 Nov 30:1-8. doi: 10.1080/00365521.2021.2007281.
    PubMed     Abstract available
    
    
    
94. CHRISTENSEN KR, Steenholdt C, Buhl S, Brynskov J, et al
    A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients' and physicians' preferences and adherence.
    Scand J Gastroenterol. 2021 Nov 13:1-8. doi: 10.1080/00365521.2021.2002397.
    PubMed     Abstract available
    
    
    
95. FURUYA Y, Fukai K, Nakazawa S, Kojimahara N, et al
    Occupational physical activity differentially affects the risk for developing later-onset Crohn's disease and ulcerative colitis among middle-aged and older populations.
    Scand J Gastroenterol. 2021 Nov 11:1-8. doi: 10.1080/00365521.2021.1999495.
    PubMed     Abstract available
    
    
    
96. TSUJII Y, Nishida T, Osugi N, Fujii Y, et al
    Classification and clinical features of adverse drug reactions in patients with ulcerative colitis treated with 5-aminosalicylate acid: a single-center, observational study.
    Scand J Gastroenterol. 2021 Nov 9:1-7. doi: 10.1080/00365521.2021.1998601.
    PubMed     Abstract available
    
    
    
97. JORISSEN C, Verstockt B, Schils N, Sabino J, et al
    Long-term clinical outcome after thiopurine discontinuation in elderly IBD patients.
    Scand J Gastroenterol. 2021;56:1323-1327.
    PubMed     Abstract available
    
    
    
98. WANG S, Zhang YR, Yu YB
    The important role of fungi in inflammatory bowel diseases.
    Scand J Gastroenterol. 2021;56:1312-1322.
    PubMed     Abstract available
    
    
    October 2021
99. LINDHAGEN S, Karling P
    A more frequent disease monitorering but no increased disease activity in patients with inflammatory bowel disease during the first year of the SARS-CoV-2 pandemic. A retrospective study.
    Scand J Gastroenterol. 2021 Oct 26:1-6. doi: 10.1080/00365521.2021.1993328.
    PubMed     Abstract available
    
    
    
100. SHIMODAIRA Y, Watanabe K, Fukuda S, Watanabe N, et al
     Limited endoscopic mucosal inflammation on equivalent to Mayo endoscopic subscore of 0 unaffect clinical relapse of ulcerative colitis.
     Scand J Gastroenterol. 2021 Oct 18:1-4. doi: 10.1080/00365521.2021.1991467.
     PubMed     Abstract available
     
     
     
101. ALIPOUR O, Lee V, Tejura TK, Wilson ML, et al
     The assessment of sarcopenia using psoas muscle thickness per height is not predictive of post-operative complications in IBD.
     Scand J Gastroenterol. 2021;56:1175-1181.
     PubMed     Abstract available
     
     
     
102. PRIMAS C, Hopf G, Reinisch S, Baumann L, et al
     Role of fecal calprotection in predicting endoscopic recurrence in postoperative Crohn's disease.
     Scand J Gastroenterol. 2021;56:1169-1174.
     PubMed     Abstract available
     
     
     September 2021
103. BAGER P, Hvas CL, Rud CL, Dahlerup JF, et al
     Long-term maintenance treatment with 300 mg thiamine for fatigue in patients with inflammatory bowel disease: results from an open-label extension of the TARIF study.
     Scand J Gastroenterol. 2021 Sep 30:1-7. doi: 10.1080/00365521.2021.1983640.
     PubMed     Abstract available
     
     
     
104. LEHTOMAKI J, Nikkonen A, Merras-Salmio L, Hiltunen P, et al
     Therapy outcome related to adalimumab trough levels in pediatric patients with inflammatory bowel disease.
     Scand J Gastroenterol. 2021 Sep 21:1-6. doi: 10.1080/00365521.2021.1977843.
     PubMed     Abstract available
     
     
     
105. ATTAUABI M, Hoglund C, Fassov J, Pedersen KB, et al
     Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases.
     Scand J Gastroenterol. 2021;56:1040-1048.
     PubMed     Abstract available
     
     
     
106. LI Y, Pan J, Zhou N, Fu D, et al
     A random forest model predicts responses to infliximab in Crohn's disease based on clinical and serological parameters.
     Scand J Gastroenterol. 2021;56:1030-1039.
     PubMed     Abstract available
     
     
     August 2021
107. VAN ERP LW, Groenen MJM, Heida W, Wisse J, et al
     Mobile application to monitor inflammatory bowel disease patients on intravenous biologic treatment: a feasibility study.
     Scand J Gastroenterol. 2021 Aug 27:1-8. doi: 10.1080/00365521.2021.1966832.
     PubMed     Abstract available
     
     
     
108. LING F, Tu L, Li J, Chen Y, et al
     Psychological aspect of patients with inflammatory bowel disease, which may be related to the quality of life, sleep and disease characteristics.
     Scand J Gastroenterol. 2021 Aug 27:1-9. doi: 10.1080/00365521.2021.1966093.
     PubMed     Abstract available
     
     
     
109. ERIKSSON C, Visuri I, Vigren L, Nilsson L, et al
     Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG.
     Scand J Gastroenterol. 2021 Aug 20:1-8. doi: 10.1080/00365521.2021.1963466.
     PubMed     Abstract available
     
     
     
110. FART F, Salihovic S, McGlinchey A, Gareau MG, et al
     Perfluoroalkyl substances are increased in patients with late-onset ulcerative colitis and induce intestinal barrier defects ex vivo in murine intestinal tissue.
     Scand J Gastroenterol. 2021 Aug 12:1-10. doi: 10.1080/00365521.2021.1961306.
     PubMed     Abstract available
     
     
     
111. KIM HM, Kim JH, Lee JK, Kang DR, et al
     Age- and sex-specific risk of colorectal cancer in incident ulcerative colitis during the first 10 years after diagnosis: a nationwide population-based study.
     Scand J Gastroenterol. 2021 Aug 10:1-7. doi: 10.1080/00365521.2021.1958370.
     PubMed     Abstract available
     
     
     
112. LUDVIGSSON JF, Holmgren J, Grip O, Halfvarson J, et al
     Adult-onset inflammatory bowel disease and rate of serious infections compared to the general population: a nationwide register-based cohort study 2002-2017.
     Scand J Gastroenterol. 2021 Aug 8:1-11. doi: 10.1080/00365521.2021.1924259.
     PubMed     Abstract available
     
     
     
113. RONNBLOM A, Ljunggren O, Karlbom U
     Complications and adverse effects related to surgical and medical treatment in patients with inflammatory bowel disease in a prospectively recruited population-based cohort.
     Scand J Gastroenterol. 2021 Aug 8:1-8. doi: 10.1080/00365521.2021.1961309.
     PubMed     Abstract available
     
     
     July 2021
114. ANISDAHL K, Svatun Lirhus S, Medhus AW, Moum B, et al
     First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study.
     Scand J Gastroenterol. 2021 Jul 28:1-6. doi: 10.1080/00365521.2021.1955147.
     PubMed     Abstract available
     
     
     
115. ATIA O, Gupta A, Travis S, Turner D, et al
     The pediatric ulcerative colitis activity index (PUCAI) predicts steroid-failure in adults with acute severe colitis.
     Scand J Gastroenterol. 2021 Jul 14:1-7. doi: 10.1080/00365521.2021.1947368.
     PubMed     Abstract available
     
     
     
116. CHEN BX, Han ZM, Zhou Q, Liu HB, et al
     Efficacy of infliximab in treatment-naive patients with stricturing small bowel Crohn's disease.
     Scand J Gastroenterol. 2021;56:812-819.
     PubMed     Abstract available
     
     
     June 2021
117. KOLEHMAINEN S, Ylisaukko-Oja T, Jokelainen J, Koivusalo M, et al
     Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting.
     Scand J Gastroenterol. 2021 Jun 21:1-8. doi: 10.1080/00365521.2021.1938206.
     PubMed     Abstract available
     
     
     
118. KRISTENSEN VA, Opheim R, Perminow G, Huppertz-Hauss G, et al
     Inflammatory bowel disease in South-Eastern Norway III (IBSEN III): a new population-based inception cohort study from South-Eastern Norway.
     Scand J Gastroenterol. 2021 Jun 21:1-7. doi: 10.1080/00365521.2021.1922746.
     PubMed     Abstract available
     
     
     
119. SIPPONEN T, Af Bjorkesten CG, Hallinen T, Ilus T, et al
     A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn's disease patients in Finland.
     Scand J Gastroenterol. 2021;56:661-670.
     PubMed     Abstract available
     
     
     
120. FORSS A, Clements M, Myrelid P, Strid H, et al
     Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE): a 16-week follow-up.
     Scand J Gastroenterol. 2021;56:680-686.
     PubMed     Abstract available
     
     
     
121. ROOSENBOOM B, Horjus Talabur Horje CS, Smids C, Leeuwis JW, et al
     Distribution of mucosal PD-1 expressing T cells in patients with colitis of different etiologies.
     Scand J Gastroenterol. 2021;56:671-679.
     PubMed     Abstract available
     
     
     May 2021
122. LOPEZ-SERRANO A, Suarez MJ, Beso P, Algarra A, et al
     Virtual chromoendoscopy with iSCAN as an alternative method to dye-spray chromoendoscopy for dysplasia detection in long-standing colonic inflammatory bowel disease: a case-control study.
     Scand J Gastroenterol. 2021 May 27:1-9. doi: 10.1080/00365521.2021.1925339.
     PubMed     Abstract available
     
     
     
123. SIGURDSSON GV, Schmidt S, Mellstrom D, Ohlsson C, et al
     Physical exercise is associated with beneficial bone mineral density and body composition in young adults with childhood-onset inflammatory bowel disease.
     Scand J Gastroenterol. 2021 May 4:1-9. doi: 10.1080/00365521.2021.1913759.
     PubMed     Abstract available
     
     
     April 2021
124. RUBIN DE CELIX C, Chaparro M, Moreno JA, Santander C, et al
     Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real-life experience.
     Scand J Gastroenterol. 2021 Apr 27:1-6. doi: 10.1080/00365521.2021.1918758.
     PubMed     Abstract available
     
     
     
125. VAN DER GIESSEN J, Fuhler GM, van der Woude CJ
     A first pregnancy seems associated with a positive effect on the course of inflammatory bowel disease: data from a prospective pregnancy cohort.
     Scand J Gastroenterol. 2021 Apr 20:1-6. doi: 10.1080/00365521.2021.1910996.
     PubMed     Abstract available
     
     
     
126. RANKALA R, Mattila K, Voutilainen M, Mustonen A, et al
     Inflammatory bowel disease-related economic costs due to presenteeism and absenteeism.
     Scand J Gastroenterol. 2021 Apr 7:1-6. doi: 10.1080/00365521.2021.1908416.
     PubMed     Abstract available
     
     
     
127. BROMS G, Soderling J, Sachs MC, Halfvarson J, et al
     Capturing biologic treatment for IBD in the Swedish Prescribed Drug Register and the Swedish National Patient Register - a validation study.
     Scand J Gastroenterol. 2021;56:410-421.
     PubMed     Abstract available
     
     
     
128. SINGH H, Nguyen T, Pho C, Giles E, et al
     Early Infliximab in Crohn's is associated with decreased intestinal surgery and similar health care costs.
     Scand J Gastroenterol. 2021;56:397-402.
     PubMed     Abstract available
     
     
     March 2021
129. MOUM KM, Moum B, Opheim R
     Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic.
     Scand J Gastroenterol. 2021 Mar 26:1-7. doi: 10.1080/00365521.2021.1901308.
     PubMed     Abstract available
     
     
     
130. BEKIC D, Belosic Halle Z
     Inflammatory bowel disease and SARS-CoV-2 pandemic: current knowledge and recommendations.
     Scand J Gastroenterol. 2021 Mar 25:1-5. doi: 10.1080/00365521.2021.1902561.
     PubMed     Abstract available
     
     
     
131. QVIST N, Vadstrup K, Alulis S, Borsi A, et al
     Increased use of biologics in the era of TNF-alpha inhibitors did not reduce surgical rate but prolonged the time from diagnosis to first time intestinal resection among patients with Crohn's disease and ulcerative colitis - a Danish register-based st
     Scand J Gastroenterol. 2021 Mar 18:1-8. doi: 10.1080/00365521.2021.1897670.
     PubMed     Abstract available
     
     
     
132. BONNAUD G, Haennig A, Altwegg R, Caron B, et al
     Real-life pilot study on the impact of the telemedicine platform EasyMICI-MaMICI((R)) on quality of life and quality of care in patients with inflammatory bowel disease.
     Scand J Gastroenterol. 2021 Mar 10:1-7. doi: 10.1080/00365521.2021.1894602.
     PubMed     Abstract available
     
     
     
133. ARBOGAST JP, Urbanik S, Schmidt R, Mennigen R, et al
     Impact of the Crohn's disease digestive damage score (Lemann Index) on the perioperative course in patients with Crohn's disease and ileocolic anastomosis.
     Scand J Gastroenterol. 2021;56:239-246.
     PubMed     Abstract available
     
     
     February 2021
134. ANKERSEN DV, Weimers P, Marker D, Teglgaard Peters-Lehm C, et al
     Costs of electronic health vs. standard care management of inflammatory bowel disease across three years of follow-up-a Danish register-based study.
     Scand J Gastroenterol. 2021 Feb 28:1-10. doi: 10.1080/00365521.2021.1892176.
     PubMed     Abstract available
     
     
     
135. RONNBLOM A, Karlbom U
     Treatment and outcome of ulcerative colitis during the first 10 years after diagnosis in a prospectively followed population-based cohort.
     Scand J Gastroenterol. 2021 Feb 12:1-7. doi: 10.1080/00365521.2021.1882553.
     PubMed     Abstract available
     
     
     January 2021
136. ERONEN H, Ilus T, Jussila A, Huhtala H, et al
     Long-term outcome of patients with acute ulcerative colitis after first course of intravenous corticosteroids.
     Scand J Gastroenterol. 2021 Jan 26:1-8. doi: 10.1080/00365521.2020.1867892.
     PubMed     Abstract available
     
     
     
137. ATTAUABI M, Burisch J, Seidelin JB
     Efficacy of ustekinumab for active perianal fistulizing Crohn's disease: a systematic review and meta-analysis of the current literature.
     Scand J Gastroenterol. 2021;56:53-58.
     PubMed     Abstract available
     
     
     
138. YANG Y, Cui X, Li J, Wang H, et al
     Clinical evaluation of vitamin D status and its relationship with disease activity and changes of intestinal immune function in patients with Crohn's disease in the Chinese population.
     Scand J Gastroenterol. 2021;56:20-29.
     PubMed     Abstract available
     
     
     December 2020
139. DORE MP, Fanciulli G, Manca A, Cocco V, et al
     Clinically relevant thyroid disorders and inflammatory bowel disease are inversely related: a retrospective case-control study.
     Scand J Gastroenterol. 2020 Dec 16:1-6. doi: 10.1080/00365521.2020.1861323.
     PubMed     Abstract available
     
     
     
140. XI W, Li Z, Ren R, Sai XY, et al
     Effect of antibiotic therapy in patients with ulcerative colitis: a meta-analysis of randomized controlled trials.
     Scand J Gastroenterol. 2020 Dec 12:1-9. doi: 10.1080/00365521.2020.1858958.
     PubMed     Abstract available
     
     
     
141. DE JONG ME, Taal E, Thomas PWA, Romkens TEH, et al
     Cross-cultural translation and validation of the IBD-control questionnaire in The Netherlands: a patient-reported outcome measure in inflammatory bowel disease.
     Scand J Gastroenterol. 2020 Dec 10:1-7. doi: 10.1080/00365521.2020.1857430.
     PubMed     Abstract available
     
     
     
142. STRIK AS, Lowenberg M, Mould DR, Berends SE, et al
     Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial.
     Scand J Gastroenterol. 2020 Dec 8:1-10. doi: 10.1080/00365521.2020.1856405.
     PubMed     Abstract available
     
     
     
143. OSTLUND I, Werner M, Karling P
     Self-monitoring with home based fecal calprotectin is associated with increased medical treatment. A randomized controlled trial on patients with inflammatory bowel disease.
     Scand J Gastroenterol. 2020 Dec 7:1-8. doi: 10.1080/00365521.2020.1854342.
     PubMed     Abstract available
     
     
     
144. KRISTJANSSON VB, Lund SH, Grondal G, Sveinsdottir SV, et al
     Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018.
     Scand J Gastroenterol. 2020 Dec 5:1-7. doi: 10.1080/00365521.2020.1854847.
     PubMed     Abstract available
     
     
     November 2020
145. LAMERS CR, de Roos NM, Bongers CCWG, Ten Haaf DSM, et al
     Repeated prolonged moderate-intensity walking exercise does not appear to have harmful effects on inflammatory markers in patients with inflammatory bowel disease.
     Scand J Gastroenterol. 2020 Nov 19:1-8. doi: 10.1080/00365521.2020.1845791.
     PubMed     Abstract available
     
     
     
146. KRISHNAPRASAD K, Walsh A, Begun J, Bell S, et al
     Crohn's Colitis Care (CCCare): bespoke cloud-based clinical management software for inflammatory bowel disease.
     Scand J Gastroenterol. 2020 Nov 8:1-8. doi: 10.1080/00365521.2020.1839960.
     PubMed     Abstract available
     
     
     
147. WALENTYNOWICZ M, Van de Pavert I, Coenen S, Fierens L, et al
     Worries and concerns of inflammatory bowel disease (IBD) patients in Belgium - a validation of the Dutch rating form.
     Scand J Gastroenterol. 2020 Nov 1:1-6. doi: 10.1080/00365521.2020.1839962.
     PubMed     Abstract available
     
     
     October 2020
148. ANKERSEN DV, Weimers P, Marker D, Johannesen T, et al
     eHealth: Disease activity measures are related to the faecal gut microbiota in adult patients with ulcerative colitis.
     Scand J Gastroenterol. 2020 Oct 12:1-10. doi: 10.1080/00365521.2020.1829031.
     PubMed     Abstract available
     
     
     April 2020
149. ZHANG CC, Voitl R, Hippchen T, Weiss KH, et al
     Evaluation of two functional CD24 polymorphisms in primary sclerosing cholangitis.
     Scand J Gastroenterol. 2020 Apr 24:1-7. doi: 10.1080/00365521.2020.1755357.
     PubMed     Abstract available
     
     
     
150. VON VOLKMANN HL, Bronstad I, Tronstad RR, Dizdar V, et al
     Plasma levels of guanylins are reduced in patients with Crohn's disease.
     Scand J Gastroenterol. 2020 Apr 20:1-5. doi: 10.1080/00365521.2020.1748224.
     PubMed     Abstract available
     
     
     
151. SHRESTHA S, Olen O, Eriksson C, Everhov AH, et al
     The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register.
     Scand J Gastroenterol. 2020;55:430-435.
     PubMed     Abstract available
     
     
     
152. ZHAO L, Tang Y, Lei N, Zhou D, et al
     Clinical features and monocyte/macrophage subsets characterization in granulomatous vs non-granulomatous Crohn's disease.
     Scand J Gastroenterol. 2020;55:442-448.
     PubMed     Abstract available
     
     
     
153. KRISTENSEN VA, Cvancarova M, Hoivik ML, Moum B, et al
     Serological antibodies and surgery in a population-based inception cohort of Crohn's disease patients - the IBSEN study.
     Scand J Gastroenterol. 2020;55:436-441.
     PubMed     Abstract available
     
     
     
154. FREITAS M, Arieira C, Carvalho PB, Rosa B, et al
     Simplify to improve in capsule endoscopy - TOP 100 is a swift and reliable evaluation tool for the small bowel inflammatory activity in Crohn's disease.
     Scand J Gastroenterol. 2020;55:408-413.
     PubMed     Abstract available
     
     
     February 2020
155. DAVIES M, Dodd S, Coultate M, Ross A, et al
     From Paris to Montreal: disease regression is common during long term follow-up of paediatric Crohn's disease.
     Scand J Gastroenterol. 2020;55:148-153.
     PubMed     Abstract available
     
     
     January 2020
156. MOLANDER P, Kemppainen H, Ilus T, Sipponen T, et al
     Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases.
     Scand J Gastroenterol. 2020;55:34-40.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.